Transaction · 0001193125-26-357383

Banerjee Subhashis

Banerjee Subhashis, CMO, reported an open-market or private sale at Artiva Biotherapeutics, Inc. involving 429.000000 shares for an estimated $5148.00. Reported holdings after the transaction were 144963.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCMO
ARTVArtiva Biotherapeutics, Inc.
Filing timeAug 20
Trade dateAug 18, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$11.14
Pre-filing
1mo ago -12.4%1w ago +5.7%1d ago +5.4%
Returns since
7d +7.2%30d +1.3%90d +1.3%180d +1.3%1y +1.3%

ARTV price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ARTV since 2026-08-20Filed 15 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-357383
Common Stock
Transaction date
Aug 18, 2026
Filed Aug 20, 2026, 01:00 AM · 2d delay
Shares
429 sh
$1.20k per share
Estimated value
-$514k
Computed from shares × price
Holdings after
144k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026.

  2. F2

    25% of the shares initially subject to the option vested and became exercisable on April 8, 2026, and the balance of the shares subject to the option are vesting and becoming exercisable at a rate of…

Original filing · 0001193125-26-357383
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ARTV